Significant differences between individual Daptomycin Cubicin agents, it seems, t, that the use of the drug selectively receiving tolterodine reported less strongly associated with constipation, the new M2 and / or M3 selective agents such as solifenacin and trospium. Evaluation of the relationship between drug pharmacokinetics, Rezeptoraffinit t, the distribution of physiological receptors, and a comparative profile of adverse effects is beyond the scope of this study, and further evaluation. Although the current results are consistent with the pharmacology of OAB agents as a class, the analysis is limited by a number of factors. First, the constipation is not a prime Re endpoint evaluated in two studies and the evaluation and documentation of the methodology constipation is an m Possible side effects vary concerning Chtlich between the studies. In recognition of the m Adjusted clinical and economic impact of constipation, the authors suggest that future clinical studies of OAB agents using standardized, validated instruments for proactive assessment and goal of this common side effect. Studies have also varied over time, the average age of patients and sex distribution. In the analysis of individual agents, there were often differences in the areas of dosage, route of administration and dosage form, all that the homogeneity t k can reduce And have implications for the interpretation of the results of study at the individual product groups. Closing Lich, the clinical severity or the number of reported constipation is not well in various Ffentlichten documented studies, so that a Sch Tzung impact of clinical and economic outcomes is not m Possible. This is particularly noteworthy because of the lack of standards in the past Ffentlichung and transmission of randomized clinical trials has been tested, and efforts were made to correct this situation. In particular, the extension presented ofreporting Consolidated Standards Tests, in the year 2004 Published to meet a number of recommendations for the regular S reporting of adverse events in study participants. In addition to improving the general explanation Tion of damage in clinical trials, f Rdern these guidelines investigators who encounter serious, severe, and previously reported side effects briefly describe all ungew Hnlichen events unfavorable briefly the type of adverse event if it occurred is the type of patients, management of adverse event, and the result of the adverse event. For testing drugs for overactive bladder, this recommendation was not always followed in various published shall report peer-reviewed. Despite this Website will RESTRICTIONS, The authors believe that this analysis is reasonable estimates Sch Of Effektst Strength for this class of drugs h Frequently used features. Because agents demonstrating modest efficacy in controlled The symptoms of overactive bladder, should be the erh Hte likelihood of a blockage in the risk and benefit assessment in the treatment considered Hyperaktivit t included are bubble, especially for patients with gastrointestinal disease is already present and older people. Similarly, the results are sufficient to justify further investigation of the frequency and clinical severity of constipation with the use of funds associated with overactive bladder. Overactive bladder is characterized by symptoms of urgency, with or without urge incontinence wi, usually.